← Back to headlines
Eli Lilly's Experimental Obesity Drug Shows Broad Benefits
Eli Lilly announced that its experimental obesity drug, retatrutide, demonstrated broad benefits, including curbing sleep apnea. The company is also making strategic moves in the vaccine market and is projected for significant growth.
Sources
Showing 0 of 2 sources
No articles available in your preferred languages.
2 articles available in other languages below.
Coverage Timeline
First report: Yahoo · 6 Jun, 20:37|Full coverage: 2 · 1h|Window: 1h
Left-leaningCenterRight-leaning
